Evidence map›Paper›PMID 29477724›Full record

ArticleThe Journal of allergy and clinical immunology2018

Loss-of-function nuclear factor κB subunit 1 (NFKB1) variants are the most common monogenic cause of common variable immunodeficiency in Europeans.

Paul Tuijnenburg, Hana Lango Allen, Siobhan O Burns, Daniel Greene, Machiel H Jansen, Emily Staples, Jonathan Stephens, Keren J Carss, Daniele Biasci, Helen Baxendale and 21 more

Open access · hybridAbstract read
In one paragraph

Article in The Journal of allergy and clinical immunology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 125 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
125citing papers in PubMed, 2 pooled it
10.5field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

125 citing papers in PubMed, 2 syntheses or guidelines pooled it, 228 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Clinical and immunological characterization ofFrontiers in immunology · 2026
    Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article

65 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

31 authors at 11 institutions in 3 countries.

Paul TuijnenburgDepartment of Pediatric Hematology, Immunology and Infectious Diseases, Emma Children's Hospital, Academic Medical Center, Amsterdam, The Netherlands; Department of Experimental Immunology, Academic Medical Center, Amsterdam, The Netherlands.
Hana Lango AllenDepartment of Haematology, University of Cambridge, Cambridge, United Kingdom; NHS Blood and Transplant Cambridge, Cambridge Biomedical Campus, Cambridge, United Kingdom.
Siobhan O BurnsDepartment of Immunology, Royal Free London NHS Foundation Trust, University College London Institute of Immunity and Transplantation, London, United Kingdom.
Daniel GreeneDepartment of Haematology, University of Cambridge, Cambridge, United Kingdom; NHS Blood and Transplant Cambridge, Cambridge Biomedical Campus, Cambridge, United Kingdom.
Machiel H JansenDepartment of Pediatric Hematology, Immunology and Infectious Diseases, Emma Children's Hospital, Academic Medical Center, Amsterdam, The Netherlands; Department of Experimental Immunology, Academic Medical Center, Amsterdam, The Netherlands.
Emily StaplesDepartment of Medicine, University of Cambridge, Cambridge, United Kingdom.
Jonathan StephensDepartment of Haematology, University of Cambridge, Cambridge, United Kingdom; NHS Blood and Transplant Cambridge, Cambridge Biomedical Campus, Cambridge, United Kingdom.
Keren J CarssDepartment of Haematology, University of Cambridge, Cambridge, United Kingdom; NHS Blood and Transplant Cambridge, Cambridge Biomedical Campus, Cambridge, United Kingdom.
Daniele BiasciDepartment of Medicine, University of Cambridge, Cambridge, United Kingdom.
Helen BaxendaleDepartment of Medicine, University of Cambridge, Cambridge, United Kingdom.
Moira ThomasDepartment of Immunology, Queen Elizabeth University Hospital, Glasgow, United Kingdom.
Anita ChandraDepartment of Medicine, University of Cambridge, Cambridge, United Kingdom.
Sorena Kiani-AlikhanDepartment of Immunology, Royal Surrey County Hospital, Guildford, United Kingdom.
Hilary J LonghurstDepartment of Immunology, Barts Health NHS Trust, London, United Kingdom.
Suranjith L SeneviratneDepartment of Immunology, Royal Free London NHS Foundation Trust, University College London Institute of Immunity and Transplantation, London, United Kingdom.
Eric OksenhendlerDepartment of Clinical Immunology, Hôpital Saint-Louis, Assistance Publique Hôpitaux de Paris (APHP), Paris, France.
Ilenia SimeoniDepartment of Haematology, University of Cambridge, Cambridge, United Kingdom.
Godelieve J de BreeDepartment of Internal Medicine, Academic Medical Center, Amsterdam, The Netherlands.
Anton T J ToolDepartment of Blood Cell Research, Sanquin Research, Amsterdam, The Netherlands.
Ester M M van LeeuwenDepartment of Experimental Immunology, Academic Medical Center, Amsterdam, The Netherlands.
Eduard H T M EbberinkDepartment of Plasma Proteins, Sanquin Research, Amsterdam, The Netherlands.
Alexander B MeijerDepartment of Plasma Proteins, Sanquin Research, Amsterdam, The Netherlands.
Salih TunaDepartment of Haematology, University of Cambridge, Cambridge, United Kingdom; NHS Blood and Transplant Cambridge, Cambridge Biomedical Campus, Cambridge, United Kingdom.
Deborah WhitehornDepartment of Haematology, University of Cambridge, Cambridge, United Kingdom; NHS Blood and Transplant Cambridge, Cambridge Biomedical Campus, Cambridge, United Kingdom.
Matthew BrownDepartment of Haematology, University of Cambridge, Cambridge, United Kingdom; NHS Blood and Transplant Cambridge, Cambridge Biomedical Campus, Cambridge, United Kingdom.
Ernest TurroDepartment of Haematology, University of Cambridge, Cambridge, United Kingdom; NHS Blood and Transplant Cambridge, Cambridge Biomedical Campus, Cambridge, United Kingdom.
Adrian J ThrasherMolecular and Cellular Immunology Section, UCL Great Ormond Street Institute of Child Health and Great Ormond Street Hospital NHS Trust London, London, United Kingdom.
Kenneth G C SmithDepartment of Medicine, University of Cambridge, Cambridge, United Kingdom.
James E ThaventhiranDepartment of Medicine, University of Cambridge, Cambridge, United Kingdom. Electronic address: jedt2@cam.ac.uk.
Taco W KuijpersDepartment of Pediatric Hematology, Immunology and Infectious Diseases, Emma Children's Hospital, Academic Medical Center, Amsterdam, The Netherlands; Department of Experimental Immunology, Academic Medical Center, Amsterdam, The Netherlands; Department of Internal Medicine, Academic Medical Center, Amsterdam, The Netherlands. Electronic address: t.w.kuijpers@amc.nl.
NIHR BioResource–Rare Diseases ConsortiumNIHR BioResource-Rare Diseases, Cambridge Biomedical Campus, Cambridge, United Kingdom.
NHS Blood and Transplant · GBUniversity of Cambridge · GBNetherlands Institute for Neuroscience · NLAmsterdam UMC Location University of Amsterdam · NLRoyal Free London NHS Foundation Trust · GBSanquin · NLBarts Health NHS Trust · GBAssistance Publique – Hôpitaux de Paris · FRGreat Ormond Street Hospital · GBQueen Elizabeth University Hospital · GBRoyal Surrey County Hospital · GB

Funding

Cancer Research UK 20406Department of Health RG65966Medical Research Council MC_EX_MR/S300011/1Medical Research Council MR/L006197/1Wellcome TrustWellcome Trust 104807/Z/14/Z
6 · The paper itself

Abstract

backgroundThe genetic cause of primary immunodeficiency disease (PID) carries prognostic information.

objectiveWe conducted a whole-genome sequencing study assessing a large proportion of the NIHR BioResource-Rare Diseases cohort.

methodsIn the predominantly European study population of principally sporadic unrelated PID cases (n = 846), a novel Bayesian method identified nuclear factor κB subunit 1 (NFKB1) as one of the genes most strongly associated with PID, and the association was explained by 16 novel heterozygous truncating, missense, and gene deletion variants. This accounted for 4% of common variable immunodeficiency (CVID) cases (n = 390) in the cohort. Amino acid substitutions predicted to be pathogenic were assessed by means of analysis of structural protein data. Immunophenotyping, immunoblotting, and ex vivo stimulation of lymphocytes determined the functional effects of these variants. Detailed clinical and pedigree information was collected for genotype-phenotype cosegregation analyses.

resultsBoth sporadic and familial cases demonstrated evidence of the noninfective complications of CVID, including massive lymphadenopathy (24%), unexplained splenomegaly (48%), and autoimmune disease (48%), features prior studies correlated with worse clinical prognosis. Although partial penetrance of clinical symptoms was noted in certain pedigrees, all carriers have a deficiency in B-lymphocyte differentiation. Detailed assessment of B-lymphocyte numbers, phenotype, and function identifies the presence of an increased CD21

conclusionWe show that heterozygous loss-of-function variants in NFKB1 are the most common known monogenic cause of CVID, which results in a temporally progressive defect in the formation of immunoglobulin-producing B cells.

Indexed as

AdolescentAdultAgedAged, 80 and overB-LymphocytesChildChild, PreschoolCommon Variable ImmunodeficiencyEuropeFemaleHumansInfantInfant, NewbornLoss of Function MutationMaleMiddle AgedNF-kappa B p50 SubunitNFKB1 protein, humanB cellscommon variable immunodeficiencynuclear factor κB1

Identifiers

PMID29477724
PMCPMC6148345
OpenAlexW2792648208

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.